Trial Profile
Japanese Anti-Coagulation Regimen Exploration in AF Catheter Ablation Registry - Rivaroxaban cohort Extension
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 23 Nov 2020
Price :
$35
*
At a glance
- Drugs Rivaroxaban (Primary)
- Indications Cerebral infarction; Embolism; Postoperative haemorrhage; Thromboembolism; Transient ischaemic attacks
- Focus Therapeutic Use
- Acronyms JACRE-REx
- 17 Nov 2020 Status changed from recruiting to completed.
- 05 Jun 2018 New trial record